Core Viewpoint - The company announces a cash dividend distribution of 0.32 CNY per share for the fiscal year 2024, approved at the shareholders' meeting on June 20, 2025 [2][4]. Distribution Plan - The total number of shares for the dividend distribution is based on the company's total share capital of 1,632,225,965 shares, resulting in a total cash dividend payout of 522,312,308.80 CNY [4]. - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the dividend record date [3]. Implementation Method - Cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with shareholders who have designated trading able to receive their dividends on the payment date [5]. - Certain shareholders, including specific trust and investment companies, will receive their dividends directly from the company [6]. Taxation Details - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, while those holding for less than one month will have their dividends fully taxed [7]. - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.288 CNY per share [8]. - Hong Kong investors will also receive a net cash dividend of 0.288 CNY per share after a 10% withholding tax [8]. - Other institutional investors will not have taxes withheld by the company, and the gross cash dividend is 0.32 CNY per share [9].

武汉市首批产业创新联合实验室系列巡礼④ 武汉市靶向小分子创新药产业创新联合实验室 今年上半年，6款1类新药在国内获批临床试验，人福医药集团股份公司（以下简称"人福医药"）创新速度令人瞩目，企业新药研发迎来"集中爆发期"。 "人福医药坚定创新驱动发展之路，连续6年将医药工业10%以上的营收投入研发。"武汉市靶向小分子创新药产业创新联合实验室（以下简称"联合实验 室"）负责人、人福医药创新药研究院院长张学军道出了创新突破背后的长期主义。 启动不到7个月，人福医药牵头14家共建单位的联合实验室已构建起"产研医金"协同网络，实现创新链与产业链"接力跑"，取得一系列创新药研发"攻坚战 果"。 △人福医药总部。 Part.1 梯队上新 时时在创新，年年有新药 8月5日，人福医药用一则公告发布了创新药研发的最新成果：人福创新药物研发中心研发的HW241045片获批进入临床试验。 "目前全球范围内没有同靶点的药物获批上市。"张学军介绍，该药物用于治疗特发性肺纤维化。对于这一导致肺功能下降的"不是癌症的癌症"，全球目前 用于治疗的仅有2款药物，主要起到延缓病程作用。此次获批临床试验的新药有望实现肺功能保持乃至回升，"将为患者带 ...

Core Points - The company announced a cash dividend of 0.32 CNY per share, totaling approximately 522.31 million CNY for all shareholders [1] - The dividend distribution plan was approved at the annual shareholders' meeting on June 20, 2025 [1] - The record date for the dividend is August 18, 2025, with the ex-dividend date also on August 19, 2025 [1][3] Dividend Distribution Details - The total number of shares for the dividend calculation is 1,632,225,965 [1] - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Taxation Information - Individual shareholders holding shares for more than one year are exempt from personal income tax on dividends [2] - For shares held for one month or less, the full dividend amount is subject to taxation [2] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied to their dividends [4]

证券代码：600079 证券简称：人福医药 公告编号：2025-100 人福医药集团股份公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.32元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/18 | － | 2025/8/19 | 2025/8/19 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经人福医药集团股份公司（以下简称"人福医药"或"公 司"）2025 年 6 月 20 日的2024年年度股东会审议通过。 二、 分配方案 除公司自行发放的对象外，其余股东的现金红利公司委托中国结算上海分公 司通过其资金清算系统向股权登记日上海证券交易所收市后登记在册并在上海证 券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者可于红利 发放日在其指定的证券营业 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the acceleration of PD-(L)1/VEGF and PD-(L)1/IL-2 dual antibodies, confirming the trend of upgrading single antibodies to multi-target therapies [5][14] - As of August 8, 2025, there are 32 PD-(L)1 tri-antibodies in clinical and preclinical stages globally, with 16 being PD-(L)1/VEGF tri-antibodies [5][14] - The report emphasizes the potential of PD-1/VEGF/IL-2 tri-target combination therapies to exhibit superior synergistic treatment effects [30][39] Summary by Sections Section 1: PD-(L)1 Dual Antibody Upgrades - The report notes the upgrade of PD-(L)1 dual antibodies, with 6 PD-(L)1/VEGF tri-antibodies entering clinical trials [5][14] - Multiple PD-(L)1/VEGF tri-antibodies show superior preclinical efficacy compared to competitors [6][16] - The PD-1/VEGF/IL-2 tri-target combination is expected to demonstrate enhanced synergistic treatment effects [30][39] Section 2: Market Performance - In the second week of August, the pharmaceutical and biotechnology sector declined by 0.84%, underperforming the CSI 300 index by 2.07 percentage points [41][46] - The medical consumables sector showed the largest increase, while the medical research outsourcing sector experienced the largest decline [46][47] Section 3: Recommended and Benefiting Companies - Recommended companies in pharmaceuticals and bioproducts include: Heng Rui Medicine, East China Pharmaceutical, Sanofi, and others [8] - CXO companies include WuXi AppTec, Tigermed, and others [8] - Companies in medical devices include Mindray Medical, United Imaging, and others [8]

Core Viewpoint - The financial performance of Renfu Pharmaceutical shows a decline in total revenue but an increase in net profit, indicating potential resilience in profitability despite revenue challenges [1] Financial Performance - As of the first quarter of 2025, the company reported total revenue of 6.137 billion yuan, a year-on-year decrease of 3.61% [1] - The net profit attributable to shareholders was 540 million yuan, reflecting a year-on-year increase of 11.09% [1] - The non-recurring net profit was 531 million yuan, showing a year-on-year growth of 14.35% [1] - The current ratio was 1.494, the quick ratio was 1.239, and the debt-to-asset ratio stood at 42.59% [1] Stock Performance - As of August 8, 2025, the stock price closed at 21.53 yuan, down by 1.01% [1] - The turnover rate was 1.02%, with a trading volume of 157,400 hands and a transaction amount of 339 million yuan [1] - There was a net outflow of main funds amounting to 34.26 million yuan, accounting for 10.11% of the transaction amount [1] Investment and Intellectual Property - Renfu Pharmaceutical has made investments in 50 external companies and participated in 18 bidding projects [2] - The company holds 364 trademark registrations and 266 patents, along with 14 administrative licenses [2] Company Background - Renfu Pharmaceutical Group Co., Ltd. was established in 1993 and is based in Wuhan, primarily engaged in the pharmaceutical manufacturing industry [1] - The registered capital of the company is approximately 1.632 billion yuan, with a paid-in capital of 387 million yuan [1]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药（维权）的李前伦、灵康药业（维 权）的隋国平、海正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈 锡飞为行业唯一一个拥有博士学历的专职 ...

| 交易日 | (路) 田樹虎城區 | | 融券会重(股) | 融券余额(元) | | --- | --- | --- | --- | --- | | 2025-08-05 | | -600.0 | 9.84万 | 215.79万 | | 2025-08-04 | | -1.87万 | 9.90万 | 217.11万 | | 2025-08-01 | | 2.54万 | 11.77万 | 256.94万 | | 2025-07-31 | | -3.48万 | 9.23万 | 201.03万 | | 2025-07-30 | | -2100.0 | 12.71万 | 279.37万 | 证券之星消息，8月5日，人福医药（600079）融资买入2476.81万元，融资偿还2412.72万元，融资净买 入64.1万元，融资余额5.54亿元，近3个交易日已连续净买入累计2364.7万元。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-05 | 64.10万 | 5.54亿 | 1.64% | | 2025-08-04 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600079 证券简称：人福医药 编号：临2025-099 四、注册分类：化学药品1类 五、申请人：武汉人福创新药物研发中心有限公司 六、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年5月21日受理的 HW241045片临床试验申请符合药品注册的有关要求，同意本品开展用于特发性肺纤维化适应症的临床 试验。 人福医药集团股份公司 关于HW241045片获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）全资子公司武汉人福创新药物研发中心有限公 司（以下简称"创新药研发中心"）近日收到国家药品监督管理局核准签发的HW241045片《药物临床试 验批准通知书》，现将相关情况公告如下： 一、药品名称：HW241045片 二、剂型：片剂 三、申请事项：境内生产药品注册临床试验 HW241045片适用于特发性肺纤维化的治疗，目前全球范围内尚无同靶点的药物获批上市。全球范围 ...

Core Viewpoint - Humanwell Healthcare Group has received approval for clinical trials of HW241045 tablets, aimed at treating idiopathic pulmonary fibrosis, a condition for which no other drugs targeting the same pathway have been approved globally [1][2]. Group 1: Drug Approval Details - The drug name is HW241045 tablets, classified as a Class 1 chemical drug, and the application was submitted by Wuhan Humanwell Innovative Drug Research Center [1]. - The approval for clinical trials was granted by the National Medical Products Administration, allowing the drug to proceed with clinical research for idiopathic pulmonary fibrosis [1][2]. Group 2: Market Context - Currently, only two drugs, Nintedanib and Pirfenidone, are approved for treating idiopathic pulmonary fibrosis, with estimated sales in 2024 of approximately RMB 1.2 billion and RMB 670 million, respectively [2]. - The cumulative R&D investment in the HW241045 project by the innovative drug research center is around RMB 23 million [2]. Group 3: Next Steps and Considerations - Following the receipt of the clinical trial approval, the innovative drug research center will initiate the necessary clinical research activities and will submit trial data to the National Medical Products Administration upon completion [2]. - The lengthy and complex process of drug development, from research to market launch, is subject to various uncertainties, which investors should be aware of [2].